Abstract
Forward genetic screens with CRISPR–Cas9 genome editing enable high-resolution detection of genetic vulnerabilities in cancer cells. We conducted genome-wide CRISPR–Cas9 screens in RNF43-mutant pancreatic ductal adenocarcinoma (PDAC) cells, which rely on Wnt signaling for proliferation. Through these screens, we discovered a unique requirement for a Wnt signaling circuit: engaging FZD5, one of the ten Frizzled receptors encoded in the human genome. Our results uncover an underappreciated level of context-dependent specificity at the Wnt receptor level. We further derived a panel of recombinant antibodies that reports the expression of nine FZD proteins and confirms that FZD5 functional specificity cannot be explained by protein expression patterns. Additionally, antibodies that specifically bind FZD5 and FZD8 robustly inhibited the growth of RNF43-mutant PDAC cells grown in vitro and as xenografts in vivo, providing orthogonal support for the functional specificity observed genetically. Proliferation of a patient-derived PDAC cell line harboring an RNF43 variant was also selectively inhibited by the FZD5 antibodies, further demonstrating their use as a potential targeted therapy. Tumor organoid cultures from colorectal carcinoma patients that carried RNF43 mutations were also sensitive to the FZD5 antibodies, highlighting the potential generalizability of these findings beyond PDAC. Our results show that CRIPSR-based genetic screens can be leveraged to identify and validate cell surface targets for antibody development and therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
20 September 2017
In the version of this article initially published, duplicate panels in Figure 5e were incorrectly used in the assembly of the figure, for which all original panels are presented in Supplementary Figure 10. The errors in Figure 5e have been corrected in the HTML and PDF versions of the article.
References
Wodarz, A. & Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14, 59–88 (1998).
Schuijers, J. & Clevers, H. Adult mammalian stem cells: the role of Wnt, Lgr5 and R-spondins. EMBO J. 31, 2685–2696 (2012).
Anastas, J.N. & Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11–26 (2013).
Polakis, P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 4 (2012).
Madan, B. & Virshup, D.M. Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs. Mol. Cancer Ther. 14, 1087–1094 (2015).
Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
Ryland, G.L. et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 7, 87 (2015).
Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573–582 (2014).
Giannakis, M. et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 46, 1264–1266 (2014).
Ivanov, I., Lo, K.C., Hawthorn, L., Cowell, J.K. & Ionov, Y. Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene 26, 2873–2884 (2007).
Koo, B.K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669 (2012).
Hao, H.X. et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485, 195–200 (2012).
Koo, B.K., van Es, J.H., van den Born, M. & Clevers, H. Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia. Proc. Natl. Acad. Sci. USA 112, 7548–7550 (2015).
Jiang, X. et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 110, 12649–12654 (2013).
Hsu, P.D., Lander, E.S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).
Hart, T. et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell 163, 1515–1526 (2015).
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096–1101 (2015).
Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80–84 (2014).
Hart, T. & Moffat, J. BAGEL: a computational framework for identifying essential genes from pooled library screens. BMC Bioinformatics 17, 164 (2016).
Hart, T., Brown, K.R., Sircoulomb, F., Rottapel, R. & Moffat, J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol. Syst. Biol. 10, 733 (2014).
Aguirre, A.J. et al. Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov. 6, 914–929 (2016).
Brinkman, E.K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).
Persson, H. et al. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J. Mol. Biol. 425, 803–811 (2013).
Gurney, A. et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. USA 109, 11717–11722 (2012).
Low, S.K. et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS One 5, e11824 (2010).
Jo, Y.S. et al. Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers. Hum. Pathol. 46, 1640–1646 (2015).
van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945 (2015).
Afelik, S., Pool, B., Schmerr, M., Penton, C. & Jensen, J. Wnt7b is required for epithelial progenitor growth and operates during epithelial-to-mesenchymal signaling in pancreatic development. Dev. Biol. 399, 204–217 (2015).
Arensman, M.D. et al. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene 33, 899–908 (2014).
Dijksterhuis, J.P. et al. Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J. Biol. Chem. 290, 6789–6798 (2015).
Bookout, A.L., Cummins, C.L., Mangelsdorf, D.J., Pesola, J.M. & Kramer, M.F. High-throughput real-time quantitative reverse transcription PCR. Curr. Protoc. Mol. Biol. 73, 15.18.1–15.8.28 (2006).
Klijn, C. et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33, 306–312 (2015).
Colwill, K. Renewable Protein Binder Working Group & Graslund, S. A roadmap to generate renewable protein binders to the human proteome. Nat. Methods 8, 551–558 (2011).
Fellouse, F.A. et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J. Mol. Biol. 373, 924–940 (2007).
Rajan, S. & Sidhu, S.S. Simplified synthetic antibody libraries. Methods Enzymol. 502, 3–23 (2012).
Acknowledgements
We wish to thank members of the Angers and Moffat labs for discussions. We are thankful to D. Hedley (Princess Margaret Hospital, Toronto, Canada) and M. Tsao (Ontario Cancer Institute, Toronto, Canada) for providing the patient-derived xenograft cells; P. Mero (Moffat lab) for help with images. This work was supported from grants funded by the Canadian Institutes for Health Research to S.A. (CIHR-273548) and J.M. (CIHR-342551) and by the Ontario Research Fund to S.S. J.M. holds a Canada Research Chair in Functional Genomics of Cancer and S.A. holds a Canada Research Chair in Functional Architecture of Signal Transduction. Some of the equipment used in this study was supported by The 3D (Diet, Digestive Tract and Disease) Centre funded by the Canadian Foundation for Innovation and Ontario Research Fund, project numbers 19442 and 30961.
Author information
Authors and Affiliations
Contributions
Conceptualization, S.A., J.M., S.S.; investigation, Z.S., Z.P., M.C., T.H., X.W., X.Z., M.R., S.J., R.O., S.F.B., J.A., K.R.B.; writing, S.A., Z.S., J.M.; funding acquisition, S.A., J.M., S.S.; supervision, S.A., J.M., S.S., H.C., and J.P.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures and Table
Supplementary Figures 1–11 and Supplementary Table 4 (PDF 4227 kb)
Supplementary Table 1
Raw read counts (XLSX 11317 kb)
Supplementary Table 2
Bayes factors (XLSX 1580 kb)
Supplementary Table 3
Differential fitness z-scores (XLSX 1314 kb)
Rights and permissions
About this article
Cite this article
Steinhart, Z., Pavlovic, Z., Chandrashekhar, M. et al. Genome-wide CRISPR screens reveal a Wnt–FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med 23, 60–68 (2017). https://doi.org/10.1038/nm.4219
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4219
This article is cited by
-
Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers
Acta Pharmacologica Sinica (2024)
-
CHSY1 promotes CD8+ T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening
Journal of Experimental & Clinical Cancer Research (2023)
-
Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens
Cancer Gene Therapy (2023)
-
Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance
Oncogenesis (2023)
-
Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes
BMC Cancer (2022)